Revisiting ‘intensive’ blood glucose control: A causal directed acyclic graph‐guided systematic review of randomized controlled trials

• Published in: Diabetes, obesity & metabolism Vol. 24; no. 12; pp. 2341 - 2352
• Main Authors: Huang, Chi‐Jung, Wang, Wei‐Ting, Sung, Shih‐Hsien, Chen, Chen‐Huan, Lip, Gregory Y. H., Cheng, Hao‐Min, Chiang, Chern‐En
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2022; Wiley Subscription Services, Inc
• Subjects: antidiabetic agents; Antidiabetics; Blood Glucose; cardiovascular events; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; dipeptidyl peptidase‐4 inhibitor; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; GLP-1 receptor agonists; Glucagon; glucagon‐like peptide‐1 receptor agonist; Glucose transporter; Glycated Hemoglobin; HbA1c; Humans; Hypoglycemia; Hypoglycemic Agents - adverse effects; Meta-analysis; Microvasculature; Patients; Peptidase; pioglitazone; Randomized Controlled Trials as Topic; Risk assessment; risk factors; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; sodium‐glucose co‐transporter‐2 inhibitor; Systematic review; Thiazolidinediones; type 2 diabetes; cardiovascular events; pioglitazone; risk factors; antidiabetic agents; type 2 diabetes; glucagon-like peptide-1 receptor agonist; sodium-glucose co-transporter-2 inhibitor; meta-analysis; dipeptidyl peptidase-4 inhibitor; HbA1c

Aim To clarify the importance of HbA1c reduction and antidiabetic drug use in preventing major adverse cardiovascular events (MACE) for patients with type 2 diabetes (T2D). Materials and Methods We conducted an updated systematic review of contemporary large randomized controlled trials assessing th...